Aldosterone: A cardiometabolic risk hormone?;Aldosterona : ¿Hormona de riesgo cardio metabólico?

Nutricion Hospitalaria

Volumn 30, Issue 6, 2014, Pages 1191-1202

  Pereira, Patrícia Feliciano ^a   Priore, Silvia Eloiza ^a   Bressan, Josefina ^a  

^a FEDERAL UNIVERSITY OF VIÇOSA   (Brazil)

Author keywords

Aldosterone; Cardiovascular diseases; Metabolic syndrome; Obesity

Indexed keywords

ALDOSTERONE;

BIOSYNTHESIS; CARDIOVASCULAR DISEASE; DIET; HUMAN; METABOLIC DISORDER; METABOLIC SYNDROME X; METABOLISM; OBESITY; RISK FACTOR;

ALDOSTERONE; CARDIOVASCULAR DISEASES; DIET; HUMANS; METABOLIC DISEASES; METABOLIC SYNDROME X; OBESITY; RISK FACTORS;

EID: 84913618035     PISSN: 02121611     EISSN: 16995198     Source Type: Journal    
DOI: 10.3305/nh.2014.30.6.7725     Document Type: Article

References (62)

1. Horton R. Aldosterone and aldosteronism. Steroids 2003;68: 1135-38.
2. White BA, Porterfiedl SP. Endocrine and reproductive physiology. Monograph series. 4 ed. Elsevier 2012. 297p.
3. Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. Hypertension 2005;46:1227-35.
4. Takeda Y, Miyamori I, Yoneda T Iki K, Hatakeyama H, Blair IA et al. Production of aldosterone in isolated rat blood vessels. Hypertension 1995;25:170-3.
5. Gomez-Sanchez CE, Zhou MY, Cozza EN, Morita H, Foecking MF, Gomez-Sanchez EP. Aldosterone biosynthesis in the rat brain. Endocrinology 1997;138:3369-73.
6. Takeda Y, Yoneda T, Demura M, Miyamori I, Mabuchi H. Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy. Endocrinology 2000; 141:1901-4.
7. Gomez-Sanchez EP, Ahmad N, Romero DG, Gomez-Sanchez CE. Origin of aldosterone in the rat heart. Endocrinology 2004;145:4796-4802.
8. Krug AW, Ehrhant-Bornstein M. Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor. Hypertension 2008;51:1252-58.
9. Marcus Y, Shefer G, Stern N. Adipose tissue rennin-angiotensin-aldosterone system (RAAS) and progression of insulin resistance. Mol Cell Endocrinol 2013;378:1-14.
10. Hillaert MA, Lentjes EG, Kemperman H, van der Graaf Y, Nathoe HM, Beygui F et al. Aldosterone, atherosclerosis and vascular events in patients with stable coronary artery disease. Int J Cardiol 2013;167:1929-35.
11. Goodfriend TL, Kelley DE, Goodpaste BH, Winters SJ. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obesity Research 1999;7(4):355-62.
12. Yamashita R, Kikuchi T, Mori Y, Aoki K, Kaburagi Y, Yasuda K et al. Aldosterone stimulates gene expression of hepatic gluconeogenic enzymes through the glucocorticoid receptor in a manner independent of the protein kinase B cascade. Endocr J 2004;51:243-51.
13. Kotlyar E, Vita JA, Winter MR, Awtry EH, Siwik DA, Keaney JF J et al. The relationship between aldosterone, oxidative stress and inflammation in chronic, stable human heart failure. J Card Fail 2006;12(2):122-7.
14. Ingelsson E, Pencina MJ, Tofler GH, Benjamin EJ, Lanier KJ, Jacques PF et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors. The Framingham Offspring Study. Circulation 2007;116:984-92.
15. Kawahito H, Yamada H, Irie D, Kato T, Akakabe Y, Kishida S et al. Periaortic adipose tissue-specific activation of the renin-angiotensin system contributes to atherosclerosis development in uninephrectomized apoE-/-mice. Am J Physiol Heart Circ Physiol 2013; 305(5):667-75.
16. Manrique CAB, DeMarco VG, Aroor AR, Mugerfeld I, Garro M, Habibi J et al. Obesity and insulin resistance induce early development of diastolic dysfunction in young female mice fed a western diet. Endocrinology 2013;154(10):3632-42.
17. Vogt B, Burnier M. Aldosterone and cardiovascular risk. Curr Hypertens Rep 2009;11:450-455.
18. Whaley-Connell A, Johnson MS, Sowers JR. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog Cardiovasc Dis 2010;52(5):401-409.
19. White P. Inherited forms of mineralocorticoid hypertension. Hypertension 1996; 28:927-36.
20. Müller J. Aldosterone: The minority hormone of the adrenal cortex. Steroids 1995;60:2-9.
21. Funder JW, Reincke M. Aldosterone: a cardiovascular risk factor? Biochim Biophys Acta 2010;1802(12):1188-92.
22. Jim F, Mogi M, Horiuchi M. Role of renin-angiotensin-aldosterone system in adipose tissue dysfunction. Mol Cell Endocrinol 2013;378:23-28.
23. Navia B, Aparicio A, Perea JM, Pérez-Farinós N, Villar-Villalba C, Labrado E et al. Sodium intake may promote weight gain; results of the FANPE study in a representative sample of the adult Spanish population. Nutr Hosp 2014;29(6):1283-89.
24. Boustany CM, Bharadwaj K, Daugherty A, Brown DR, Randall DC, Cassis LA. Activation of the systemic and adipose rennin-angiotensin system in rats with diet-induced obesity and hypertension. Am J Physiol Regul Integr Comp Physiol 2004;287:943-49.
25. Conway V, Couture P, Gauthier S, Pouliot Y, Lamarche B. Effect of buttermilk consumption on blood pressure in moderately hypercholesterolemic men and women. Nutrition 2014;30(1):116-19.
26. Graudal NA, Hubeck-Graudal T, Jürgens G. Effects of low-sodium diet vs. high-sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride. Am J Hypertens 2012;25(1):1-15.
27. Whaley-Connell AT, Habibi J, Aroor A, Ma L, Hayden MR, Ferrario CM et al. Salt loading exacerbates diastolic dysfunction and cardiac remodeling in young female Ren2 rats. Metabolism 2013;62(12):1761-71.
28. Mao CA, Liu R, Bo L. High-salt diets during pregnancy affected fetal and offspring renal renin-angiotensin system. J Endocrinol 2013;128(1): 61-73.
29. Appel LJ and American Society of Hypertension Writing Group. ASH position paper: dietary approaches to lower blood pressure. J Clin Hypertens 2009;11(7):358-68.
30. Furuhashi M, Ura N, Takizawa H, Yoshida D, Moniwa N, Murakami H et al. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens 2004;22(10):1977-82.
31. Wada TA, Miyashita Y, Sasaki M, Aruga Y, Nakamura Y, Ishii Y et al. Eplerenone ameliorates the phenotypes of metabolic syndrome with NASH in liver-specific SREBP-1c Tg mice fed high-fat and high-fructose diet. Am J Physiol Endocrinol Metab 2013;305(11):1415-25.
32. Sherajee SJ, Rafiq K, Nakano D, Mori H, Kobara H, Hitomi H et al. Aldosterone aggravates glucose intolerance induced by high fructose. Eur J Pharmacol 2013; 720(15):63-68.
33. Bays HE, Toth PP, Kris Etherton, Abate N, Aronne LJ, Brown WV et al. Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association. J Clin Lipidol 2013;7:304-83.
34. Canale MP, di Villahermosa SM, Martino G, Rovella V, Noce A, De Lorenzo A et al. Obesity-related metabolic syndrome: mechanisms of sympathetic overactivity. Int J Endocrinol 2013;2013:865-965.
35. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005;96(9):939-49.
36. Giacchetti G, Faloia E, Mariniello B, Sardu C, Gatti C, Camilloni MA et al. Overexpression of the rennin-angiotensin system in human visceral adipose tissue in normal and overweight subjects. Am J Hypertens 2002;15:381-88.
37. Yu Z, Eckert GJ, Liu H, Pratt JH, Tu W. Adiposity has unique influence on the renin-aldosterone axis and blood pressure in black children. J Pediatr 2013;163(5):1317-22.
38. Kidambi S, Kotchen JM, Grim CE, Raff H, Mao J, Singh RJ et al. Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension 2007;49:704-11.
39. Dall’Asta C, Vedani P, Manunta P, Pizzocri P, Marchi M, Paganelli M et al. Effect of weight loss through laparoscopic gastric banding on blood pressure, plasma renin activity and aldosterone levels in morbid obesity. Nutr Metab Cardiovasc Dis 2009;19:110-14.
40. Huan Y, DeLoach S, Keith SW, Goodfriend TL, Falkner B. Aldosterone and aldosterone: renin ratio associations with insulin resistance and blood pressure in African Americans. J Am Soc Hypertens 2012;6(1): 56-65.
41. Goodfriend TL, Egan B, Stepniakowski K, Ball DL. Relationships among plasma aldosterone, high-density lipoprotein cholesterol, and insulin in humans. Hypertension 1995;25:30-36.
42. Kathiresan S, Larson MG, Benjamin EJ, Corey D, Murabito JM, Fox CS et al. Clinical and genetic correlates of serum aldosterone in the community: the Framingham Heart Study. Am J Hypertens 2005;18:657-65.
43. Bochud M, Nussberger J, Bovet P, Maillard MR, Elston RC, Paccaud F et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 2006;48:239-45.
44. Strauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky J Jr et al. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003;17(5):349-52.
45. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C et al. A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients. J Am Coll Cardiol 2006;48:2293-2300.
46. Sowers JR, Whaley-Connell A, Epstein M. The emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistance hypertension. Ann Intern Med 2009;150:776-83.
47. Ikeda K, Isaka T, Fujioka K, Manome Y, Tojo K. Suppression of aldosterone synthesis and secretion by ca(2+) channel antagonists. Int J Endocrinol 2012; 2012: 519467.
48. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004;351:33-41.
49. Yoshimotoa T, Hirata Y. Aldosterone as a cardiovascular risk hormone. J Endocrinol 2007;54(3):359-70.
50. Mayyas F, Alzoubi KH, Van Wagoner DR. Impact of aldosterone antagonists on the substrate for atrial fibrillation: Aldosterone promotes oxidative stress and atrial structural/electrical remodeling. Int J Cardiol 2013;166(6):5135-42.
51. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT et al. Aldosterone induced inflammation in the heart: role of oxidative stress. Am J Pathol 2002;161:1773-81.
52. Tzamou V, Vyssoulis G, Karpanou E, Kyvelou SM, Gialernios T, Stefanadis C et al. Aldosterone levels and inflammatory stimulation in essential hypertensive patients. J Hum Hypertens 2013;27:535-38.
53. Siwik DA, Colucci WS. Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium. Heart Fail Rev 2004;9 (1):43-51.
54. Egan BM, Papademetriou V, Wofford M, Calhoun D, Fernandes J, Riehle JE et al. Metabolic syndrome and insulin resistance in the TROPHY sub-study: Contrasting views in patients with high-normal blood pressure. Am J Hypertens 2005;18(1):3-12.
55. Enomoto S, Yoshiyama M, Omura, Matsumoto R, Kusuyama T, Kim S T et al. Effects of eplerenone on transcriptional factors and mRNA expression related RO cardiac remodeling after myocardic infarction. Heart 2005;91(12):1595-1600.
56. Cooper JN, Fried L, Tepper P, Barinas-Mitchell E, Conroy MB, Evans RW et al. Changes in serum aldosterone are associated with changes in obesity-related factors in normotensive overweight and obese young adults. Hypertens Res 2013;36(10):895-901.
57. Abad-Cardiel M, Alvarez-Álvarez B, Luque-Fernandez L, Fernández C, Fernández-Cruz A, Martell-Claros N et al. Hypertension caused by primary hyperaldosteronism: increased heart damage and cardiovascular risk. Rev Esp Cardiol 2013;66(1):47-52.
58. Savard S, Amar L, Plouin PF, Steicheb O. Cardiovascular complications associated with primary aldosteronism: A controlled cross-sectional study. Hypertension 2013; 62(2):331-36.
59. Dartsch T, Fischer R, Gapelyuk A, Weiergraeber M, Ladage D, Schneider T et al. Aldosterone induces electrical remodeling independent of hypertension. Int J Cardiol 2013;5(164):170-78.
60. Peer M, Boaz M, Zipora M, Shargorodsky M. Determinants of left ventricular hypertrophy in hypertensive patients: identification of high-risk patients by metabolic, vascular, and inflammatory risk factors. Int J Angiol 2013;22(4):223-28.
61. Tomaschitz A, Pilz S, Ritz E, Boehm BO, März W. Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk Cardiovascular Health Study (LURIC). Eur Heart J 2010;31(10):1237-47.
62. Ori Y, Chagnac A, Korzets A, Zingerman B, Herman-Edelstein M, Bergman M et al. Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone. Nephrol Dial Transplant 2013;28(7):1787-93.